Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain

Abdominoplasty Clinical Trial

Official title:

Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain After Mini-abdominoplasty Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04182880
• Other study ID #: CPL-01_AB_001
• Status: Completed
• Phase: Phase 2
• Start date: January 6, 2020
• Est. completion date: February 28, 2020

Study information

• Verified date: August 2022
• Source: Cali Pharmaceuticals LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in patients after mini-abdominoplasty

Description:

This is a randomized, double-blind, study to evaluate the safety, PK profile of CPL-01 for the management of postoperative pain after mini-abdominoplasty surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 28, 2020
• Est. primary completion date: February 28, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subject provides signed, written informed consent before participation in the study.
• Subject is aged =18 and =70 years at the time of informed consent and is male or female.
• Subject is scheduled to undergo elective mini-abdominoplasty surgery under general anesthesia without collateral procedures.
• Female subjects are eligible only if all the following apply:

1. Not pregnant

2. Not breastfeeding

3. Not planning to become pregnant during participation in the study

4. Committed to the use of an acceptable form of birth control for the duration of the study until at least 30 days after administration of IP.

• Male subjects must commit to the use of a reliable method of birth control for the duration of the study until at least 30 days after administration of IP or be surgically sterile (biologically or surgically).
• Subject is free of any physical, mental, or medical conditions which, in the opinion of the investigator, make mini-abdominoplasty or study participation inadvisable.

Exclusion Criteria:

• Subject has known, suspected, or reported history of alcohol or drug abuse or dependence within the previous 2 years as assessed by the investigator
• Subject has impaired liver function (e.g., aspartate aminotransferase/alanine aminotransferase greater than 3 times the upper limit of the reference range, bilirubin greater than 1.5 times the upper limit of the reference range unless due to Gilbert's syndrome, active hepatic disease, evidence of clinically significant liver disease, or other condition such as alcoholism, cirrhosis, or hepatitis, etc.) that suggests the potential for an increased susceptibility to hepatic toxicity with IP exposure.
• Subject has clinically significant renal abnormalities (creatinine =1.5 × upper limit of normal).
• Subject has hemoglobin A1c =7.0%.
• Subject has participated in another clinical study and/or received an IP (marketed or premarket) within 30 days before surgery.
• Subject has a history of, or positive test results for, human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibody at Screening.
• Subject with an upper respiratory infection/cough in the 14 days before surgery.
• Subjects with a history of significant postoperative nausea and vomiting.

Related Conditions & MeSH terms

• Abdominoplasty
• Pain, Postoperative

Intervention

Drug:
• CPL-01
CPL-01 will be administered
• Placebo
Placebo will be administered

Locations

Country	Name	City	State
United States	Chesapeake Research Group	Pasadena	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Cali Pharmaceuticals LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean (Peak) Plasma Concentration (Cmax)	Mean Cmax of 573 ng/mL and occurred at approximately 13 hours. Timepoints tested included before study drug administration and 15, 30, and 45 minutes and 1, 2, 4, 6, 8, 10, 12, 18, 24, 30, 36, 48, 60, 72, 96, and 120 hours after administration.	Baseline through 120 hours after start of study drug administration